Northern Trust Corp increased its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 18.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,394,511 shares of the company's stock after purchasing an additional 371,886 shares during the quarter. Northern Trust Corp owned approximately 0.61% of Recursion Pharmaceuticals worth $16,187,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Susquehanna Fundamental Investments LLC acquired a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $882,000. Syon Capital LLC acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $159,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Recursion Pharmaceuticals by 17.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 131,990 shares of the company's stock valued at $893,000 after purchasing an additional 19,552 shares in the last quarter. Hsbc Holdings PLC lifted its stake in shares of Recursion Pharmaceuticals by 48.2% in the 4th quarter. Hsbc Holdings PLC now owns 36,339 shares of the company's stock valued at $249,000 after purchasing an additional 11,822 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 9.7% in the 4th quarter. MetLife Investment Management LLC now owns 149,808 shares of the company's stock valued at $1,013,000 after purchasing an additional 13,267 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the company. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Morgan Stanley dropped their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Finally, Needham & Company LLC dropped their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $7.60.
View Our Latest Research Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Stock Down 1.2%
RXRX stock traded down $0.06 during midday trading on Tuesday, hitting $4.45. 2,082,507 shares of the company's stock were exchanged, compared to its average volume of 22,716,266. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36. The firm has a 50 day moving average price of $5.31 and a 200-day moving average price of $6.58. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -2.91 and a beta of 0.99.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. Recursion Pharmaceuticals's revenue for the quarter was up 7.2% compared to the same quarter last year. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Recursion Pharmaceuticals Profile
(
Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
